-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $16,633.36 in Stock
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $16,633.36 in Stock
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) insider Gwenn Hansen sold 1,412 shares of the business's stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $11.78, for a total value of $16,633.36. Following the sale, the insider now owns 23,009 shares in the company, valued at $271,046.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Nurix Therapeutics Trading Up 0.6 %
Shares of NRIX traded up $0.07 during trading hours on Wednesday, hitting $12.36. 264,824 shares of the stock traded hands, compared to its average volume of 289,377. Nurix Therapeutics, Inc. has a 1-year low of $7.52 and a 1-year high of $20.20. The firm has a market capitalization of $582.75 million, a PE ratio of -3.32 and a beta of 1.63. The business has a fifty day moving average of $11.65 and a 200-day moving average of $13.46.
Get Nurix Therapeutics alerts:Analysts Set New Price Targets
A number of analysts have weighed in on the company. Morgan Stanley assumed coverage on Nurix Therapeutics in a research report on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 price target on the stock. SVB Leerink lowered their price target on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a research report on Tuesday, December 13th. Finally, HC Wainwright lowered their price target on Nurix Therapeutics to $53.00 in a research report on Thursday, October 13th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $32.90.
Hedge Funds Weigh In On Nurix Therapeutics
Large investors have recently made changes to their positions in the company. Los Angeles Capital Management LLC lifted its stake in shares of Nurix Therapeutics by 410.0% during the third quarter. Los Angeles Capital Management LLC now owns 67,655 shares of the company's stock valued at $882,000 after acquiring an additional 54,390 shares during the period. Amalgamated Bank acquired a new position in shares of Nurix Therapeutics during the first quarter valued at $70,000. Denali Advisors LLC acquired a new position in shares of Nurix Therapeutics during the third quarter valued at $47,000. ARK Investment Management LLC increased its holdings in Nurix Therapeutics by 65.2% in the third quarter. ARK Investment Management LLC now owns 1,286,522 shares of the company's stock valued at $16,763,000 after purchasing an additional 507,797 shares during the last quarter. Finally, DAFNA Capital Management LLC increased its holdings in Nurix Therapeutics by 4.3% in the second quarter. DAFNA Capital Management LLC now owns 566,695 shares of the company's stock valued at $7,180,000 after purchasing an additional 23,351 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company's stock.Nurix Therapeutics Company Profile
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
NURIX治疗公司(纳斯达克代码:NRIX-GET评级)内部人士格温·汉森在1月30日(星期一)的一笔交易中出售了1,412股该公司的股票。这些股票的平均价格为11.78美元,总价值为16,633.36美元。出售后,这位内部人士现在拥有该公司23,009股,价值271,046.02美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在美国证券交易委员会网站。
Nurix治疗公司股价上涨0.6%
在周三的交易时间里,NRIX的股价上涨了0.07美元,达到12.36美元。该股有264,824股易手,而其平均成交量为289,377股。Nurix Treateutics,Inc.的一年低点为7.52美元,一年高位为20.20美元。该公司市值为5.8275亿美元,市盈率为-3.32,贝塔系数为1.63。该业务的50日移动均线切入位为11.65美元,200日移动均线切入位为13.46美元。
到达纽瑞克斯治疗公司警报:分析师设定新的价格目标
许多分析师都对该公司发表了看法。摩根士丹利在10月11日星期二的一份研究报告中承担了对Nurix Treateutics的报道。他们对该股给予了“同等权重”的评级和11.00美元的目标价。SVB Leerink在12月13日(星期二)的一份研究报告中将Nurix Treateutics的目标价从37.00美元下调至28.00美元,并对该股设定了“跑赢大盘”的评级。最后,在10月13日星期四的一份研究报告中,HC Wainwright将他们对Nurix治疗公司的目标价下调至53.00美元。一位研究分析师对该股的评级为持有,七位分析师对该公司的评级为买入。根据MarketBeat.com的数据,该公司目前的平均评级为“中等买入”,共识目标价为32.90美元。
对冲基金入股Nurix Treeutics
大型投资者最近对他们在该公司的头寸进行了调整。洛杉矶资本管理有限责任公司在第三季度增持了纽瑞克斯治疗公司的股份410.0%。洛杉矶资本管理有限责任公司在此期间增持了54,390股,现在拥有67,655股该公司股票,价值882,000美元。合并银行在第一季度收购了Nurix治疗公司的新股票,价值7万美元。Denali Advisors LLC在第三季度收购了Nurix治疗公司股票的新头寸,价值4.7万美元。方舟投资管理有限责任公司在第三季度增持了65.2%的Nurix Treateutics股份。方舟投资管理有限责任公司现在拥有1,286,522股该公司的股票,价值16,763,000美元,在上个季度又购买了507,797股。最后,达夫纳资本管理有限责任公司在第二季度增持了4.3%的Nurix Treeutics股份。达夫纳资本管理有限责任公司现在拥有566,695股该公司的股票,价值7,180,000美元,在上个季度又购买了23,351股。机构投资者和对冲基金持有该公司91.33%的股票。纽瑞克斯治疗公司简介
(获取评级)
Nurix治疗公司是一家生物制药公司,专注于治疗癌症和免疫疾病的小分子疗法的发现、开发和商业化。该公司开发了用于治疗复发或难治性B细胞恶性肿瘤的口服布鲁顿酪氨酸激酶(BTK)降解剂NX-2127;用于治疗复发或难治性B细胞恶性肿瘤和自身免疫性疾病的口服生物可用BTK降解剂NX-5948;以及口服可用于免疫肿瘤学适应症的Casitas B细胞性淋巴瘤原癌基因B(CBL-B)抑制剂NX-1607。
另请参阅
- 免费获取StockNews.com关于Nurix治疗的研究报告(NRIX)
- Bed Bath&Beyond正在绕着排水沟走
- Allegro MicroSystems是一只定位良好的半导体股票
- 斯科特奇迹-Gro触底,比赛逆转
- 奥驰亚是一只大衰退的股票,长期前景不确定
- Novavax的股价在1月份大幅上涨,而其他股票则出现下滑
接受《Nurix治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nurix Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧